Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lipocine (LPCN) Return on Equity (2016 - 2025)

Historic Return on Equity for Lipocine (LPCN) over the last 13 years, with Q3 2025 value amounting to 0.35%.

  • Lipocine's Return on Equity fell 1500.0% to 0.35% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.35%, marking a year-over-year decrease of 1500.0%. This contributed to the annual value of 0.0% for FY2024, which is 5800.0% up from last year.
  • Per Lipocine's latest filing, its Return on Equity stood at 0.35% for Q3 2025, which was down 1500.0% from 0.25% recorded in Q2 2025.
  • In the past 5 years, Lipocine's Return on Equity registered a high of 0.11% during Q3 2022, and its lowest value of 0.76% during Q4 2023.
  • Moreover, its 5-year median value for Return on Equity was 0.33% (2023), whereas its average is 0.3%.
  • In the last 5 years, Lipocine's Return on Equity soared by 17800bps in 2021 and then tumbled by -7400bps in 2023.
  • Over the past 5 years, Lipocine's Return on Equity (Quarter) stood at 0.02% in 2021, then plummeted by -1714bps to 0.29% in 2022, then tumbled by -160bps to 0.76% in 2023, then skyrocketed by 100bps to 0.0% in 2024, then plummeted by -84197bps to 0.35% in 2025.
  • Its last three reported values are 0.35% in Q3 2025, 0.25% for Q2 2025, and 0.27% during Q1 2025.